- /
- Supported exchanges
- / US
- / CERT.NASDAQ
Certara Inc (CERT NASDAQ) stock market data APIs
Certara Inc Financial Data Overview
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Certara Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Certara Inc data using free add-ons & libraries
Get Certara Inc Fundamental Data
Certara Inc Fundamental data includes:
- Net Revenue: 422 M
- EBITDA: 94 250 K
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-04
- EPS/Forecast: 0.06
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Certara Inc News
New
Certara (CERT) Stock Fair Value Edges Higher As Analysts Weigh Turnaround Progress
Price targets for Certara are clustering in the mid to high single digits, with recent moves centering around the US$9 to US$10 range. These shifts reflect mixed analyst views as models are refreshed ...
In-Silico Drug Discovery Market Report Now Available: Capitalize on AI-led R&D disruption as revenue surges from $3.3B to $6B by 2030; benchmark Certara, Insilico Medicine, Isomorphic Labs, Exscientia and BenevolentAI to secure share.
Company Logo AI, cloud and HPC are accelerating virtual screening and precision medicine, expanding adoption across pharma, biotech and CROs in oncology, neurology, rare and infectious diseases. Dub...
Capitalize on Drug Discovery Informatics: Benchmark Schrödinger, Certara, Dotmatics, Thermo Fisher and BIOVIA to Accelerate R&D ROI and Secure Market Advantage
Company Logo AI, machine learning and big data are advancing virtual screening and precision medicine, creating opportunities in molecular modeling, docking and data integration. Dublin, Sept. 22, 2...
Capitalize on Biosimulation’s R&D Disruption: Benchmark Certara, Simulations Plus, Dassault Systèmes, Schrödinger and Applied BioMath to Accelerate Drug Pipelines and Secure ROI
Company Logo Biosimulation adoption is rising in drug development, driven by AI, personalized medicine, regulatory support and R&D cost savings, with strong opportunities in services and Asia-Pacific...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.